New study tracks how a Gut-Joint drug works in real time
NCT ID NCT07602517
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 75 adults with Crohn's disease or ulcerative colitis who are starting guselkumab, a drug used for inflammatory bowel disease. Researchers want to see if the drug also helps with joint pain and stiffness linked to spondyloarthritis. Participants will report symptoms and have blood tests over one year. The goal is to learn more about how the drug affects both gut and joint health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can group learning make biotherapy safer for arthritis patients?
- Gentle tai chi may get spondyloarthritis patients moving